Literature DB >> 1817466

Nicotine potentiation of haloperidol in reducing tic frequency in Tourette's disorder.

B J McConville1, M H Fogelson, A B Norman, W M Klykylo, P Z Manderscheid, K W Parker, P R Sanberg.   

Abstract

In an open, nonblind study, 10 patients with Tourette's disorder who were being treated with haloperidol were videotaped before, while, and after chewing nicotine gum. The frequency of tics was reduced significantly during the 30-minute gum-chewing period and during the 1 hour after gum chewing. Nicotine appears to potentiate haloperidol effects in patients with Tourette's disorder.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1817466     DOI： 10.1176/ajp.148.6.793

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN： 0002-953X            Impact factor:   18.112


  10 in total

Review 1.  Translating laboratory discovery to the clinic: from nicotine and mecamylamine to Tourette's, depression, and beyond.

Authors:  Paul R Sanberg; Cecilia Vindrola-Padros; R Douglas Shytle
Journal:  Physiol Behav       Date:  2012-07-06

Review 2.  Potential Therapeutic Application for Nicotinic Receptor Drugs in Movement Disorders.

Authors:  Maryka Quik; James T Boyd; Tanuja Bordia; Xiomara Perez
Journal:  Nicotine Tob Res       Date:  2019-02-18       Impact factor: 4.244

3.  Nicotine effects on adults with attention-deficit/hyperactivity disorder.

Authors:  E D Levin; C K Conners; E Sparrow; S C Hinton; D Erhardt; W H Meck; J E Rose; J March
Journal:  Psychopharmacology (Berl)       Date:  1996-01       Impact factor: 4.530

Review 4.  Smoking in patients receiving psychotropic medications: a pharmacokinetic perspective.

Authors:  H D Desai; J Seabolt; M W Jann
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

Review 5.  Nicotinic receptor mechanisms and cognition in normal states and neuropsychiatric disorders.

Authors:  Kristi A Sacco; Katie L Bannon; Tony P George
Journal:  J Psychopharmacol       Date:  2004-12       Impact factor: 4.153

6.  Treatment strategies for tics in Tourette syndrome.

Authors:  Clare M Eddy; Hugh E Rickards; Andrea E Cavanna
Journal:  Ther Adv Neurol Disord       Date:  2011-01       Impact factor: 6.570

Review 7.  Pharmacological options for the treatment of Tourette's disorder.

Authors:  F J Jiménez-Jiménez; P J García-Ruiz
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 8.  The pharmacology of Tourette syndrome.

Authors:  Roji Thomas; Andrea E Cavanna
Journal:  J Neural Transm (Vienna)       Date:  2013-01-30       Impact factor: 3.575

Review 9.  Role for the nicotinic cholinergic system in movement disorders; therapeutic implications.

Authors:  Maryka Quik; Danhui Zhang; Xiomara A Perez; Tanuja Bordia
Journal:  Pharmacol Ther       Date:  2014-05-14       Impact factor: 12.310

10.  European clinical guidelines for Tourette syndrome and other tic disorders. Part II: pharmacological treatment.

Authors:  Veit Roessner; Kerstin J Plessen; Aribert Rothenberger; Andrea G Ludolph; Renata Rizzo; Liselotte Skov; Gerd Strand; Jeremy S Stern; Cristiano Termine; Pieter J Hoekstra
Journal:  Eur Child Adolesc Psychiatry       Date:  2011-04       Impact factor: 4.785
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.